From non-adherence to adherence: Can innovative solutions resolve a longstanding problem? DOI Creative Commons
Przemysław Kardas

European Journal of Internal Medicine, Journal Year: 2023, Volume and Issue: 119, P. 6 - 12

Published: Oct. 15, 2023

Non-adherence to medication is a longstanding problem, profoundly affecting patient outcomes and sustainability of healthcare systems. Historically, non-adherence has been observed since the time Hippocrates, however, when potent drugs became available in midst 20th century, it pivotal concern. Despite numerous studies interventions designed, adherence rates remain suboptimal, currently reaching about 50 % still, as described WHO report two decades ago. What worse, many professionals feel neither responsible nor able change it.Enhancing requires in-depth understanding concept, intuitive approaches fail work. For example, contrary expectations, education alone proves insufficient addressing this issue. Both behavioural models recent experience reflecting low acceptance COVID-19 vaccinations strongly suggest that patients' decisions are driven by emotions, which often results intentional non-adherence.Several technical innovations, such smart inhalers electronic pill dispensers, offer potential solutions. However, their effectiveness varies, standardized certification procedures lacking. Altogether, solutions do not eliminate problem entirely. To move forward, social health system innovation equally needed. Multiple stakeholders could benefit from improved adherence, therefore greater involvement advisable create an adherence-supporting environment.In conclusion, despite evidence-based interventions, remains complex challenge. Technical combined with shift policy priorities, lead better outcomes. The global tide non-communicable chronic conditions, aging societies urges us take seriously.

Language: Английский

Determinants of COVID-19 vaccine fatigue DOI Creative Commons
Tanja Stamm, Julia Partheymüller, Erika Mosor

et al.

Nature Medicine, Journal Year: 2023, Volume and Issue: 29(5), P. 1164 - 1171

Published: March 27, 2023

There is growing concern that Coronavirus Disease 2019 (COVID-19) vaccine fatigue will be a major obstacle in maintaining immunity the general population. In this study, we assessed acceptance future scenarios two conjoint experiments, investigating determinants such as new vaccines, communication, costs/incentives and legal rules. The experiments were embedded an online survey (n = 6,357 participants) conducted European countries (Austria Italy). Our results suggest vaccination campaigns should tailored to subgroups based on their status. Among unvaccinated, campaign messages conveying community spirit had positive effect (0.343, confidence interval (CI) 0.019-0.666), whereas offering incentives, cash reward (0.722, CI 0.429-1.014) or voucher (0.670, 0.373-0.967), was pivotal decision-making of those vaccinated once twice. triple vaccinated, readiness increased when adapted vaccines offered (0.279, 0.182-0.377), but costs (-0.795, -0.935 -0.654) medical dissensus (-0.161, -0.293 -0.030) reduced likelihood get vaccinated. We conclude failing mobilize likely result booster rates falling short expectations. For long-term success, measures fostering institutional trust considered. These provide guidance responsible for COVID-19 campaigns.

Language: Английский

Citations

58
Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023 DOI Creative Commons
Jeffrey V. Lazarus, Trenton M. White, Katarzyna Wyka

et al.

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(6), P. 1559 - 1563

Published: April 29, 2024

Abstract It is unclear how great a challenge pandemic and vaccine fatigue present to public health. We assessed perspectives on coronavirus disease 2019 (COVID-19) routine immunization as well trust in information sources future preparedness survey of 23,000 adults 23 countries October 2023. The participants reported lower intent get COVID-19 booster 2023 (71.6%), compared with 2022 (87.9%). A total 60.8% expressed being more willing vaccinated for diseases other than result their experience during the pandemic, while 23.1% less willing. Trust 11 selected each averaged 7 10-point scale one’s own doctor or nurse World Health Organization, averaging 6.9 6.5, respectively. Our findings emphasize that hesitancy challenges remain health practitioners, underscoring need targeted, culturally sensitive communication strategies.

Language: Английский

Citations

36
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial DOI Creative Commons
Fengcai Zhu, Shoujie Huang, Xiaohui Liu

et al.

The Lancet Respiratory Medicine, Journal Year: 2023, Volume and Issue: 11(12), P. 1075 - 1088

Published: Nov. 16, 2023

The live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine (dNS1-RBD, Pneucolin; Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) confers long-lasting and broad protection in animal models is, to our knowledge, the first COVID-19 mucosal enter into human trials, but its efficacy is still unknown. We aimed assess safety (but not immunogenicity) of dNS1-RBD against COVID-19.

Language: Английский

Citations

43
The influence of COVID-19 risk perception and vaccination status on the number of social contacts across Europe: insights from the CoMix study DOI Creative Commons
James Wambua, Neilshan Loedy, Christopher I Jarvis

et al.

BMC Public Health, Journal Year: 2023, Volume and Issue: 23(1)

Published: July 13, 2023

The SARS-CoV-2 transmission dynamics have been greatly modulated by human contact behaviour. To curb the spread of virus, global efforts focused on implementing both Non-Pharmaceutical Interventions (NPIs) and pharmaceutical interventions such as vaccination. This study was conducted to explore influence COVID-19 vaccination status risk perceptions related number social contacts individuals in 16 European countries.

Language: Английский

Citations

30
An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza DOI Creative Commons
Man Xing, Gaowei Hu, Xiang Wang

et al.

npj Vaccines, Journal Year: 2024, Volume and Issue: 9(1)

Published: March 21, 2024

Abstract Despite prolonged surveillance and interventions, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) influenza viruses continue to pose a global health burden. Thus, we developed chimpanzee adenovirus-based combination vaccine, AdC68-HATRBD, with dual specificity against SARS-CoV-2 virus. When used as standalone intranasal immunization AdC68-HATRBD induced comprehensive potent immune responses consisting of immunoglobin (Ig) G, mucosal IgA, neutralizing antibodies, memory T cells, which protected mice from BA.5.2 pandemic H1N1 infections. heterologous booster, markedly improved protective response licensed or vaccine. Therefore, whether administered intranasally booster this vaccine is valuable strategy enhance overall efficacy by inducing robust systemic responses, thereby conferring lines immunological defenses for these two viruses.

Language: Английский

Citations

18
COVID-19 Vaccine Hesitancy: Umbrella Review of Systematic Reviews and Meta-Analysis DOI Creative Commons

Tahani Al Rahbeni,

Prakasini Satapathy, Ramaiah Itumalla

et al.

JMIR Public Health and Surveillance, Journal Year: 2024, Volume and Issue: 10, P. e54769 - e54769

Published: April 30, 2024

The unprecedented emergence of the COVID-19 pandemic necessitated development and global distribution vaccines, making understanding vaccine acceptance hesitancy crucial to overcoming barriers vaccination achieving widespread immunization.

Language: Английский

Citations

17
SARS-CoV-2 correlates of protection from infection against variants of concern DOI
Kaiyuan Sun, Jinal N. Bhiman, Stefano Tempia

et al.

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(10), P. 2805 - 2812

Published: July 26, 2024

Language: Английский

Citations

16
Dynamic predictors of COVID-19 vaccination uptake and their interconnections over two years in Hong Kong DOI Creative Commons
Jiehu Yuan, Yucan Xu, Irene Wong

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Jan. 4, 2024

Abstract The global rollout of COVID-19 vaccines faces a significant barrier in the form vaccine hesitancy. This study adopts dynamic and network perspective to explore determinants uptake Hong Kong, focusing on multi-level their interconnections. Following framework proposed by Strategic Advisory Group Experts (SAGE), used repeated cross-sectional surveys map these at multiple levels investigates interconnections simultaneously sample 15,179 over two years. results highlight nature hesitancy an evolving pandemic. findings suggest that confidence attitudes play crucial roles vaccination uptake, with importance shifting time. initial emphasis safety gradually transitioned heightened consideration effectiveness later stage. also highlights impact chronic condition, age, case numbers, non-pharmaceutical preventive behaviours uptake. Higher educational attainment being married were associated primary booster it may be possible leverage groups as early innovation adopters. Trust government acts bridging factor linking various variables networks attitudes, which subsequently closely linked provides insights for designing future effective programmes changing circumstances.

Language: Английский

Citations

12
Vaccine hesitancy and trust in sub-Saharan Africa DOI Creative Commons
Kerstin Unfried, Jan Priebe

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: May 13, 2024

Abstract Lack of trust is a primary reason behind the global rise in vaccine hesitancy. Existing research on trust—vaccine hesitancy nexus has almost exclusively focused COVID-19 with vast majority studies examining industrialized countries. In this study, we investigated influence different policy-relevant actors (government, science, media, pharmaceutical companies, society) for recently available vaccines related to polio and HPV which benchmark against vaccine. Leveraging unique data 5203 individuals from six countries (Ghana, Kenya, Nigeria, South Africa, Tanzania, Uganda), showed that individuals’ government society are key predictors Furthermore, demonstrated these relationships remarkably stable across vaccine, disease, country contexts.

Language: Английский

Citations

10
Are we Ready for the Next Pandemic? Public Preferences and Trade-offs Between Vaccine Characteristics and Societal Restrictions Across 21 countries DOI Creative Commons
Marcello Antonini, Mesfin G. Genie, Katie Attwell

et al.

Social Science & Medicine, Journal Year: 2025, Volume and Issue: 366, P. 117687 - 117687

Published: Jan. 16, 2025

Language: Английский

Citations

2